Home
H3 Biomedicine

H3 Biomedicine Market Share Analysis for December 2025

Health > Biotechnology and Pharmaceuticals

Domainh3biomedicine.com

Year Founded2011

Employees51 - 200

Annual Revenue$15M - $25M

H3 Biomedicine

H3 Biomedicine (including company regionals)

h3biomedicine.com

See more website traffic and engagement information

H3 Biomedicine Revenue up to December 2025 is 15M - 25M

revenue generated by H3 Biomedicine top domains

H3 Biomedicine top domains revenue over 3 years

Revenue for H3 Biomedicine top domains

h3biomedicine.com15M - 25M

See more with Sales Intelligence

Total visits to H3 Biomedicine's top domains

Understand H3 Biomedicine market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in H3 Biomedicine's top domains

Analyze H3 Biomedicine engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on H3 Biomedicine's top domains

See how H3 Biomedicine keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

H3 Biomedicine top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by H3 Biomedicine

These are the website technologies, by industry, used by H3 Biomedicine top domains

Email Services (2)

G Suite

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Advertising (1)

adresult

More Technologies

6

See all

News & Signals from H3 Biomedicine

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsH3biomedicine is developing five clinical-stage drugs.Founded in 2010 as a subsidiary of Eisai, H3 had been developing five clinical-stage drugs for a variety of cancers.

NewsH3biomedicine hired Richard Woodman as Board of Directors on Jan 10th '22.H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D. to its Board of Directors ("Board").

NewsH3biomedicine launched update on intratumoral E7766 clinical program for advanced solid tumors on Oct 8th '21.H3 Biomedicine today announced an update on intratumoral E7766 clinical program for advanced solid tumors or lymphomas at AACR-NCI-EORTC.